Anne Lesage Sells 20,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Anne Lesage sold 20,000 shares of the company’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $38.27, for a total transaction of $765,400.00. Following the completion of the transaction, the insider directly owned 73,969 shares of the company’s stock, valued at $2,830,793.63. This represents a 21.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Anne Lesage also recently made the following trade(s):

• On Thursday, September 10th, Anne Lesage sold 30,000 shares of Pharvaris stock. The shares were sold at an average price of $38.30, for a total value of $1,149,000.00.
• On Tuesday, June 30th, Anne Lesage sold 30,703 shares of Pharvaris stock. The shares were sold at an average price of $35.49, for a total value of $1,089,649.47.
• On Tuesday, June 30th, Anne Lesage sold 27,872 shares of Pharvaris stock. The stock was sold at an average price of $35.48, for a total value of $988,898.56.
• On Monday, June 29th, Anne Lesage sold 6,997 shares of Pharvaris stock. The stock was sold at an average price of $35.05, for a total value of $245,244.85.
• On Monday, June 29th, Anne Lesage sold 10,600 shares of Pharvaris stock. The shares were sold at an average price of $35.07, for a total value of $371,742.00.

Pharvaris Stock Down 1.0%

NASDAQ PHVS traded down $0.35 during trading hours on Monday, reaching $36.02. The company’s stock had a trading volume of 653,689 shares, compared to its average volume of 412,750. Pharvaris N.V. has a 1 year low of $20.65 and a 1 year high of $43.25. The company has a market capitalization of $2.36 billion, a price-to-earnings ratio of -11.81 and a beta of -2.33. The firm’s 50-day moving average price is $35.37 and its 200-day moving average price is $31.75.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Equities research analysts anticipate that Pharvaris N.V. will post -3.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Pharvaris

Several institutional investors have recently bought and sold shares of PHVS. venBio Partners LLC purchased a new position in shares of Pharvaris in the 2nd quarter worth $160,569,809. Wellington Management Group LLP raised its position in shares of Pharvaris by 12.9% during the 2nd quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock valued at $82,748,000 after buying an additional 274,034 shares in the last quarter. Commodore Capital LP lifted its holdings in shares of Pharvaris by 1.6% in the 1st quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock valued at $54,211,000 after acquiring an additional 29,525 shares during the last quarter. 5AM Venture Management LLC purchased a new position in Pharvaris in the second quarter worth about $27,581,008. Finally, Seven Fleet Capital Management LP grew its position in Pharvaris by 144.6% in the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock worth $26,782,000 after acquiring an additional 457,804 shares in the last quarter.

Analysts Set New Price Targets

A number of brokerages have issued reports on PHVS. Leerink Partners lifted their price target on shares of Pharvaris from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. New Street Research set a $60.00 price objective on shares of Pharvaris in a report on Friday, August 14th. HSBC raised Pharvaris to an “overweight” rating in a report on Thursday, August 13th. Rosenblatt Securities set a $60.00 target price on Pharvaris in a research report on Wednesday, September 9th. Finally, Wells Fargo & Company increased their price target on Pharvaris from $55.00 to $65.00 and gave the company an “overweight” rating in a research note on Wednesday, September 9th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $59.87.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.